Consortium working with medical authorities on approval for Covid-19 rapid test

A consortium that includes medical diagnostics company Omega is working with the Medicines and Healthcare products Regulatory Agency (MHRA) to enable approval for its Covid-19 lateral flow antibody test.

The Alva-based company is part of the consortium led by AIM-listed Abingdon Health developing the AbC-19 Rapid Test.

Abingdon, which is York-based, said that while the UK’s Department of Health and Social Care has first refusal of supplies of the test through a contract that runs to 14 February, it is also working on potential international distribution.

The UK Rapid Test Consortium liaising with customers and regulatory authorities across a total of 27 international territories, to allow future use of the product outside of the UK.

Omega Diagnostics CEO Colin King said: “We welcome the update from Abingdon Health this morning and we look forward to being able to update investors on this approval process for self-test use in due course.

“We remain confident that the AbC-19 Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world.”

Abingdon Health raised £22m with a listing on the Alternative Investment Market on 15 December.


READ  Veggie food firm Quorn slammed for wrongly claiming Brits would lower carbon footprint by eating its product


Please enter your comment!
Please enter your name here